Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Clinical Oncology

• Publication date

  2003-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2003.05.002PMID 14673039
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

  2003cited by this paper
• Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

  2003cited by this paper
• Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma

  2001cited by this paper
• Cancer Statistics, 2001

  2001cited by this paper
• Delivering adjuvant chemotherapy to women with early‐stage breast carcinoma

  2001cited by this paper
• Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer.

  2000cited by this paper
• 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

  2000cited by this paper
• The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?

  2000cited by this paper
• General guidelines for the management of older patients with cancer.

  2000cited by this paper
• A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care.

  2000cited by this paper
• A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer

  2000cited by this paper
• Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

  2000cited by this paper
• What threshold for adjuvant therapy in older breast cancer patients?

  2000cited by this paper
• Adjuvant therapy for breast cancer.

  2000cited by this paper
• Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.

  1999cited by this paper
• Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer.

  1998cited by this paper
• A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity.

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Dose intensity of standard adjuvant cmf with G-CSF for premenopausal node-positive breast cancer patients.

  1998cited by this paper
• First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy.

  1998cited by this paper
• Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.

  1998cited by this paper
• Use of G-CSF to Sustain Dose Intensity in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Pilot Study.

  1996cited by this paper
• Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer.

  1996cited by this paper
• Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.

  1995cited by this paper
• Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

  1994cited by this paper
• Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.

  1994cited by this paper
• Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.

  1993cited by this paper
• Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial.

  1992cited by this paper
• Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.

  1991cited by this paper
• Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

  1991cited by this paper
• Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe

  1990cited by this paper
• Combination chemotherapy as an adjuvant treatment in operable breast cancer.

  1976cited by this paper

• Association between modifications in intravenous chemotherapy dose and disease-free survival and related influencing factors in lung cancer patients: a retrospective study based on inverse probability weighting

  2026cites this paper
• Teaching cancer patients undergoing chemotherapy in the National Health Service to use daily self-moxibustion to reduce chemotherapy-induced pancytopenia: a feasibility study

  2026cites this paper
• Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancer.

  2025cites this paper
• Patient factors and modifications to intended chemotherapy for women with Stages I–IIIA breast cancer

  2025cites this paper
• Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer.

  2025cites this paper
• Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer

  2025cites this paper
• Exercise May Improve Completion of Standard and Emerging Cancer Treatments.

  2025cites this paper
• Electronic symptom monitoring improves chemotherapy dose intensity in neoadjuvant chemotherapy for breast cancer.

  2025cites this paper
• The Optimal Timing and Duration of Daily G‐CSF for the Primary Prevention of Febrile Neutropenia in Breast Cancer Patients Undergoing Adjuvant TAC Chemotherapy

  2025cites this paper
• Low relative dose intensity adjuvant chemotherapy in elderly patients with breast cancer: predictors and impact on survival.

  2025cites this paper
• Risk-Stratified Management of ADC drug-Related Neutropenia: Integrating Clinical Trial Meta-Summary and Existing Guideline Principles.

  2025cites this paper
• Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing Study

  2025cites this paper
• Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter Analysis

  2025cites this paper
• The usefulness of immunonutrition in chemotherapy and chemoradiotherapy for esophageal cancer.

  2025cites this paper
• Incidence, characteristics, and clinical impact of serious adverse events in patients with breast cancer receiving antineoplastic treatment in the ambulatory setting

  2024cites this paper
• Clinicopathological Factors and Interleukin-6 Levels Associated With Low Relative Dose Intensity in Women With Breast Cancer Receiving First-Line Chemotherapy

  2024cites this paper
• Dose delay, dose reduction, and early treatment discontinuation in Black and White women receiving chemotherapy for nonmetastatic breast cancer

  2024cites this paper
• Metastatic recurrence in women diagnosed with non-metastatic breast cancer: a systematic review and meta-analysis

  2024cites this paper
• Decreasing polypharmacy in older adults with cancer: A pilot cluster-randomized trial protocol

  2024cites this paper
• Exploring the Potential Role of Phytopharmaceuticals in Alleviating Toxicities of Chemotherapeutic Agents.

  2024cites this paper
• Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicity

  2024cites this paper
• Advanced Body Measurement Techniques Can Complement Current Methods of Cytotoxic Chemotherapy Dose Prescription

  2024cites this paper
• Does Haematological Toxicity Increase with the Use of Lipophilic Chemotherapeutic Agents in Obese Breast Cancer Patients?

  2024cites this paper
• Reduction in chemotherapy relative dose intensity decreases overall survival of neoadjuvant chemoradiotherapy in patients with locally advanced esophageal carcinoma

  2024cites this paper
• Harnessing physical activity monitoring and digital biomarkers of frailty from pendant based wearables to predict chemotherapy resilience in veterans with cancer

  2024cites this paper
• The impact of non- and anthracycline-based chemotherapy on fatigue in breast cancer survivors: results from WF-97415

  2024cites this paper
• Romiplostim in chemotherapy‐induced thrombocytopenia: A review of the literature

  2024cites this paper
• Two decades of pegfilgrastim: what have we learned? Where do we go from here?

  2023cites this paper
• Assessment of breast cancer chemotherapy dose reduction in an integrated healthcare delivery system

  2023cites this paper
• Association of self-directed walking with toxicity moderation during chemotherapy for the treatment of early breast cancer

  2023cites this paper
• The Impact of HIV Infection on Neoadjuvant and Adjuvant Chemotherapy Relative Dose Intensity in South African Patients with Breast Cancer

  2023cites this paper
• Body mass index and patient-reported function, quality of life and treatment toxicity in women receiving adjuvant chemotherapy for breast cancer

  2023cites this paper
• Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia

  2023cites this paper
• Retrospective analysis of the impact of dose delay and reduction on outcomes of colorectal cancer patients treated with FOLFIRI‑based treatment

  2023cites this paper
• Dose Delays, Dose Reductions, and Relative Total Dose Intensity in Patients With Advanced Cancer Who Exercised During Neoadjuvant Chemotherapy Treatment

  2023cites this paper
• A nomogram for predicting breast cancer specific survival in elderly patients with breast cancer: a SEER population-based analysis

  2023cites this paper
• Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study

  2022cites this paper
• The Protective Effect of Sweet Potato Root Tuber on Chemotherapy-Induced Thrombocytopenia.

  2022cites this paper
• The Impact of Age on Assessment and Treatment of Breast Cancer in Older People: You Are Only as Old as Your Oncologist Thinks You Are ….

  2022cites this paper
• The Effect Of Neutropenia On The Delivery Of Chemotherapy In Breast Cancer Patients At Korle Bu Teaching Hospital In Accra, Ghana

  2022cites this paper
• Risk of febrile neutropenia in very elderly patients aged ≥80 years receiving their first cycle of R‐CHOP regimen: a nationwide real‐world study in Japan

  2022cites this paper
• Chemotherapy limiting neutropenia. Is prevention required?

  2022cites this paper
• Long-term antimüllerian hormone patterns differ by cancer treatment exposures in young breast cancer survivors.

  2022cites this paper
• Chemotherapy and anticancer drugs adjustment in obesity: a narrative review.

  2022cites this paper
• A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices

  2022cites this paper
• Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial

  2022influential citation
• Mitigating acute chemotherapy-associated adverse events in patients with cancer

  2022cites this paper
• Chemotherapy-Induced Toxicities and Their Associations with Clinical and Non-Clinical Factors among Breast Cancer Patients in Vietnam

  2022cites this paper
• Granulocyte Colony-Stimulating Factor Utilization and Prescribing Patterns in Cancer Patients: A Single Institution Experience of a Saudi Cancer Center

  2022cites this paper
• An interactive mobile application versus an educational booklet to promote job retention in women undergoing adjuvant chemotherapy for breast cancer: a randomized controlled trial

  2022cites this paper
• Impact of body mass index on pathological complete response and survival of breast cancer patients receiving neoadjuvant chemotherapy

  2022cites this paper
• Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy

  2021influential citation
• Exploring the Barriers Related to the Healthcare System and Healthcare Professionals in Implementing Quality Intravenous Chemotherapy: A Qualitative Study

  2021cites this paper
• Retrospective cohort analysis of prescription patterns of cancer medications during periods of drug stockouts in Botswana

  2021cites this paper
• Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity

  2021influential citation
• Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity

  2021cites this paper
• Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer

  2021cites this paper
• Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy.

  2021cites this paper
• Association of Obesity with Worse Operative and Oncologic Outcomes for Patients Undergoing Gastric Cancer Resection

  2021cites this paper
• Primary prophylaxis with pegfilgrastim during the first cycle of R-CHOP to avoid reduction of dose intensity in elderly patients

  2021cites this paper
• Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper

  2021cites this paper
• Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars

  2021cites this paper
• Efficacy and Safety of Lipegfilgrastim in Lung Cancer Patients Receiving Myelosuppressive Chemotherapy in a Real-World Setting: Results of an Analysis of Pooled Data from Two Non-Interventional European Studies

  2021cites this paper
• Exploring the barriers related to the healthcare system in implementing quality intravenous chemotherapy: a qualitative study

  2021cites this paper
• Cellular and Molecular Players in the Interplay between Adipose Tissue and Breast Cancer

  2021cites this paper
• Our experience of nursing/allied health practitioner led geriatric screening and assessment of older patients with cancer - a highly accessible model of care.

  2021cites this paper
• The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients

  2020cites this paper
• A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study

  2020cites this paper
• Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice

  2020cites this paper
• Risk Associated with Severe Hematological Toxicity in Patients with Urothelial Cancer Receiving Combination Chemotherapy of Gemcitabine and Cisplatin

  2020cites this paper
• Primary prophylaxis with pegfilgrastim in patients with newly-diagnosed diffuse large B-cell lymphoma: propensity score and instrumental variable analyses

  2020cites this paper
• Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.

  2020cites this paper
• Impact of body mass index on overall survival in patients with metastatic breast cancer

  2020cites this paper
• Budget impact analysis of pegfilgrastim biosimilar in the treatment of febrile neutropenia in Italy

  2020cites this paper
• Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000–1

  2020cites this paper
• Impact of chemotherapy schedule modification on breast cancer patients: a single-centre retrospective study

  2020cites this paper
• Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.

  2020cites this paper
• Patterns of Anthracycline-Based Chemotherapy-Induced Adverse Drug Reactions and Their Impact on Relative Dose Intensity among Women with Breast Cancer in Ethiopia: A Prospective Observational Study

  2020cites this paper
• Effects of Exercise on Cancer Treatment Completion and Efficacy

  2020cites this paper
• Роль пролонгированных гранулоцитарных колониестимулирующих факторов в профилактике фебрильной нейтропении у пациентов, получающих двухнедельные

  2020cites this paper
• Eflapegrastim, a Long‐Acting Granulocyte‐Colony Stimulating Factor for the Management of Chemotherapy‐Induced Neutropenia: Results of a Phase III Trial

  2020cites this paper
• Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study

  2019cites this paper
• Thrombosis and Hemostasis in Cancer

  2019cites this paper
• Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study

  2019cites this paper
• Let's talk about cytotoxic chemotherapy dosing: unravelling adjustments and off‐protocol prescribing

  2019cites this paper
• Management of Thrombocytopenia in Cancer Patients.

  2019cites this paper
• Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment

  2019cites this paper
• The evolution of value with filgrastim in oncology.

  2019cites this paper
• A Phase 2, International, Multicenter, Open-label Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients With Solid Tumors Undergoing Myelosuppressive Chemotherapy

  2019cites this paper
• The long-term social value of granulocyte colony-stimulating factors.

  2019cites this paper
• Impact of Essential Medicine Stock Outs on Cancer Therapy Delivery in a Resource-Limited Setting

  2019cites this paper
• Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma

  2019cites this paper
• CYP2J2∗7 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients

  2019cites this paper
• Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective.

  2019cites this paper
• Impact of exercise on chemotherapy completion rate: A systematic review of the evidence and recommendations for future exercise oncology research.

  2019cites this paper
• Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years

  2019cites this paper
• The Impact of Age and Adjuvant Chemotherapy Modifications on Survival Among Black Women With Breast Cancer.

  2019cites this paper
• Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995–2015

  2019cites this paper
• Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials

  2019cites this paper
• Early breast cancer: why does obesity affect prognosis?

  2018cites this paper